# K Dane Wittrup

List of Publications by Year
in descending order



| 191 | 16,701 | 14614 66 | 17546 121 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 195 | 195 | 195 | 15982 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Yeast surface display for screening combinatorial polypeptide libraries. Nature Biotechnology, 1997, 15, 553-557. | 9.4 | 1,579 |
| 2 | Isolating and engineering human antibodies using yeast surface display. Nature Protocols, 2006, 1, 755-768. | 5.5 | 792 |
| 3 | A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Molecular Cancer Therapeutics, 2009, 8, 2861-2871. | 1.9 | 497 |
| 4 | Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Advanced Drug Delivery Reviews, 2008, 60, 1421-1434. | 6.6 | 471 |
| 5 | Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nature Biotechnology, 2003, 21, 163-170. | 9.4 | 462 |
| 6 | Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nature Medicine, 2016, 22, 1402-1410. | 15.2 | 437 |
| 7 | Biophysical properties of the clinical-stage antibody landscape. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 944-949. | 3.3 | 433 |
| 8 | Monovalent, reduced-size quantum dots for imaging receptors on living cells. Nature Methods, 2008, 5, 397-399. | 9.0 | 398 |
| 9 | Yeast surface display for protein engineering and characterization. Current Opinion in Structural Biology, 2007, 17, 467-473. | 2.6 | 366 |
| 10 | Computational design of antibody-affinity improvement beyond in vivo maturation. Nature Biotechnology, 2007, 25, 1171-1176. | 9.4 | 310 |
| 11 | Enhanced CARâ€“T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science, 2019, 365, 162-168. | 6.0 | 282 |
| 12 | [25] Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods in Enzymology, 2000, 328, 430-444. | 0.4 | 280 |
| 13 | Increasing the secretory capacity of Saccharomyces cerevisiae for production of single-chain antibody fragments. Nature Biotechnology, 1998, 16, 773-777. | 9.4 | 244 |
| 14 | Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. Journal of Clinical Investigation, 2017, 127, 2176-2191. | 3.9 | 241 |
| 15 | Design Criteria for Engineering Inorganic Material- Specific Peptides. Langmuir, 2005, 21, 6929-6933. | 1.6 | 198 |
| 16 | Protein engineering by cell-surface display. Current Opinion in Biotechnology, 2001, 12, 395-399. | 3.3 | 186 |
| 17 | Protein Disulfide Isomerase Overexpression Increases Secretion of Foreign Proteins in Saccharomyces cerevisiae. Bio/technology, 1994, 12, 381-384. | 1.9 | 185 |
| 18 | Directed evolution of a secretory leader for the improved expression of heterologous proteins and fullâ€length antibodies in Saccharomyces cerevisiae. Biotechnology and Bioengineering, 2009, 103, 1192-1201. | 1.7 | 181 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity. Cancer Research, 2013, 73, 1547-1558. | 0.4 | 176 |
| 20 | Factors determining antibody distribution in tumors. Trends in Pharmacological Sciences, 2008, 29, 57-61. | 4.0 | 174 |
| 21 | Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17616-17621. | 3.3 | 173 |
| 22 | Manipulating the Selection Forces during Affinity Maturation to Generate Cross-Reactive HIV Antibodies. Cell, 2015, 160, 785-797. | 13.5 | 173 |
| 23 | Aglycosylated immunoglobulin G<sub>1</sub>variants productively engage activating Fc receptors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20167-20172. | 3.3 | 169 |
| 24 | Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2. Cancer Cell, 2015, 27, 489-501. | 7.7 | 158 |
| 25 | Picomolar Affinity Fibronectin Domains Engineered Utilizing Loop Length Diversity, Recursive Mutagenesis, and Loop Shuffling. Journal of Molecular Biology, 2008, 381, 1238-1252. | 2.0 | 148 |
| 26 | Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Engineering, Design and Selection, 2013, 26, 663-670. | 1.0 | 147 |
| 27 | Practical Theoretic Guidance for the Design of Tumor-Targeting Agents. Methods in Enzymology, 2012, 503, 255-268. | 0.4 | 143 |
| 28 | Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Science Translational Medicine, 2019, 11, . | 5.8 | 141 |
| 29 | Fine Affinity Discrimination by Yeast Surface Display and Flow Cytometry. Biotechnology Progress, 2000, 16, 31-37. | 1.3 | 140 |
| 30 | Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Research, 2003, 63, 1288-96. | 0.4 | 140 |
| 31 | Soluble IL-2RA Levels in Multiple Sclerosis Subjects and the Effect of Soluble IL-2RA on Immune Responses. Journal of Immunology, 2009, 182, 1541-1547. | 0.4 | 136 |
| 32 | Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13252-13257. | 3.3 | 135 |
| 33 | Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37ÂC. Protein Engineering, Design and Selection, 2004, 17, 293-304. | 1.0 | 130 |
| 34 | Fine Epitope Mapping of anti-Epidermal Growth Factor Receptor Antibodies Through Random Mutagenesis and Yeast Surface Display. Journal of Molecular Biology, 2004, 342, 539-550. | 2.0 | 129 |
| 35 | Optimal Screening of Surface-Displayed Polypeptide Libraries. Biotechnology Progress, 1998, 14, 55-62. | 1.3 | 127 |
| 36 | Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ TÂcell immunity. Immunity, 2022, 55, 308-323.e9. | 6.6 | 126 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Five birds, one stone: Neutralization of Î±-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs, 2015, 7, 243-254. | 2.6 | 125 |
| 38 | Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor. Journal of Biological Chemistry, 2004, 279, 30375-30384. | 1.6 | 122 |
| 39 | Engineering Antibody Affinity by Yeast Surface Display. Methods in Enzymology, 2004, 388, 348-358. | 0.4 | 121 |
| 40 | Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity. Nature Cancer, 2020, 1, 882-893. | 5.7 | 113 |
| 41 | Protein Folding Stability Can Determine the Efficiency of Escape from Endoplasmic Reticulum Quality Control. Journal of Biological Chemistry, 1998, 273, 19453-19458. | 1.6 | 110 |
| 42 | Theoretic Criteria for Antibody Penetration into Solid Tumors and Micrometastases. Journal of Nuclear Medicine, 2007, 48, 995-999. | 2.8 | 108 |
| 43 | Quantitative Spatiotemporal Analysis of Antibody Fragment Diffusion and Endocytic Consumption in Tumor Spheroids. Cancer Research, 2008, 68, 3334-3341. | 0.4 | 106 |
| 44 | High-affinity lamprey VLRA and VLRB monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12891-12896. | 3.3 | 104 |
| 45 | A modular IgG-scFv bispecific antibody topology. Protein Engineering, Design and Selection, 2010, 23, 221-228. | 1.0 | 104 |
| 46 | An Integrating Vector for Tunable, High Copy, Stable Integration into the Dispersed Ty Î´ Sites of Saccharomyces cerevisiae. Biotechnology Progress, 1996, 12, 16-21. | 1.3 | 102 |
| 47 | Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3320-3325. | 3.3 | 97 |
| 48 | Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Molecular Cancer Therapeutics, 2008, 7, 2233-2240. | 1.9 | 96 |
| 49 | Evolution of an Interloop Disulfide Bond in High-Affinity Antibody Mimics Based on Fibronectin Type III Domain and Selected by Yeast Surface Display: Molecular Convergence with Single-Domain Camelid and Shark Antibodies. Journal of Molecular Biology, 2007, 368, 1024-1041. | 2.0 | 95 |
| 50 | Selection of Horseradish Peroxidase Variants with Enhanced Enantioselectivity by Yeast Surface Display. Chemistry and Biology, 2007, 14, 1176-1185. | 6.2 | 94 |
| 51 | Development of a Human Light Chain Variable Domain (VL) Intracellular Antibody Specific for the Amino Terminus of Huntingtin via Yeast Surface Display. Journal of Molecular Biology, 2004, 342, 901-912. | 2.0 | 93 |
| 52 | Crystal Structure of an HSA/FcRn Complex Reveals Recycling by Competitive Mimicry of HSA Ligands at a pH-Dependent Hydrophobic Interface. Structure, 2013, 21, 1966-1978. | 1.6 | 93 |
| 53 | Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. Journal of Immunological Methods, 2004, 287, 147-158. | 0.6 | 90 |
| 54 | Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. Nucleic Acids Research, 2004, 32, 36e-36. | 6.5 | 89 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Bispecific Designed Ankyrin Repeat Proteins (DARPins) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor Recycling. Journal of Biological Chemistry, 2011, 286, 41273-41285. | 1.6 | 89 |
| 56 | Immunotherapy: The Path to Win the War on Cancer?. Cell, 2015, 161, 185-186. | 13.5 | 86 |
| 57 | A mechanistic compartmental model for total antibody uptake in tumors. Journal of Theoretical Biology, 2012, 314, 57-68. | 0.8 | 85 |
| 58 | Protein Engineering and Selection Using Yeast Surface Display. Methods in Molecular Biology, 2015, 1319, 3-36. | 0.4 | 83 |
| 59 | Reduction of BiP Levels Decreases Heterologous Protein Secretion in Saccharomyces cerevisiae. Journal of Biological Chemistry, 1996, 271, 10017-10022. | 1.6 | 82 |
| 60 | Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunology, Immunotherapy, 2008, 57, 1879-1890. | 2.0 | 80 |
| 61 | A small-molecule catalyst of protein folding in vitro and in vivo. Chemistry and Biology, 1999, 6, 871-879. | 6.2 | 79 |
| 62 | Secretion Efficiency inSaccharomyces cerevisiaeof Bovine Pancreatic Trypsin Inhibitor Mutants Lacking Disulfide Bonds Is Correlated with Thermodynamic Stabilityâ€. Biochemistry, 1998, 37, 1264-1273. | 1.2 | 78 |
| 63 | Highly avid magnetic bead capture: An efficient selection method for de novo protein engineering utilizing yeast surface display. Biotechnology Progress, 2009, 25, 774-783. | 1.3 | 77 |
| 64 | Stability and CDR Composition Biases Enrich Binder Functionality Landscapes. Journal of Molecular Biology, 2010, 401, 84-96. | 2.0 | 76 |
| 65 | High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs, 2015, 7, 770-777. | 2.6 | 76 |
| 66 | Quantitative Screening of Yeast Surface-Displayed Polypeptide Libraries by Magnetic Bead Capture. Biotechnology Progress, 2002, 18, 212-220. | 1.3 | 73 |
| 67 | Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5082-5087. | 3.3 | 69 |
| 68 | Convergent Potency of Internalized Gelonin Immunotoxins across Varied Cell Lines, Antigens, and Targeting Moieties. Journal of Biological Chemistry, 2011, 286, 4165-4172. | 1.6 | 66 |
| 69 | Stochastic kinetics of intracellular huntingtin aggregate formation. Nature Chemical Biology, 2006, 2, 319-323. | 3.9 | 65 |
| 70 | Rapid tolerization of virus-activated tumor-specific CD8 <sup>+</sup> T cells in prostate tumors of TRAMP mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13003-13008. | 3.3 | 65 |
| 71 | Yeast Surface Display for Antibody Isolation: Library Construction, Library Screening, and Affinity Maturation. Methods in Molecular Biology, 2014, 1131, 151-181. | 0.4 | 65 |
| 72 | Degradation of Mutated Bovine Pancreatic Trypsin Inhibitor in the Yeast Vacuole Suggests Post-endoplasmic Reticulum Protein Quality Control. Journal of Biological Chemistry, 2004, 279, 15289-15297. | 1.6 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | High-Affinity CD25-Binding IL-2 Mutants Potently Stimulate Persistent T Cell Growthâ€. Biochemistry, 2005, 44, 10696-10701. | 1.2 | 63 |
| 74 | Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast. Proteins: Structure, Function and Bioinformatics, 2005, 62, 1026-1035. | 1.5 | 62 |
| 75 | High-throughput phenotypic screen and transcriptional analysis identify new compounds and targets for macrophage reprogramming. Nature Communications, 2021, 12, 773. | 5.8 | 62 |
| 76 | A33 antigen displays persistent surface expression. Cancer Immunology, Immunotherapy, 2008, 57, 1017-1027. | 2.0 | 61 |
| 77 | Probing the interface between biomolecules and inorganic materials using yeast surface display and genetic engineering. Acta Biomaterialia, 2005, 1, 145-154. | 4.1 | 60 |
| 78 | Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. AAPS Journal, 2016, 18, 635-646. | 2.2 | 60 |
| 79 | Peptide tags for enhanced cellular and protein adhesion to single-crystalline sapphire. Biotechnology and Bioengineering, 2007, 97, 1009-1020. | 1.7 | 59 |
| 80 | Interleukin-2 mutants with enhanced Â-receptor subunit binding affinity. Protein Engineering, Design and Selection, 2003, 16, 1081-1087. | 1.0 | 58 |
| 81 | Lack of CD8 <sup>+</sup> T cell effector differentiation during priming mediates checkpoint blockade resistance in nonâ€“small cell lung cancer. Science Immunology, 2021, 6, eabi8800. | 5.6 | 58 |
| 82 | Improved mutants from directed evolution are biased to orthologous substitutions. Protein Engineering, Design and Selection, 2006, 19, 245-253. | 1.0 | 57 |
| 83 | Rapid Conformational Epitope Mapping of Anti-gp120 Antibodies with a Designed Mutant Panel Displayed on Yeast. Journal of Molecular Biology, 2013, 425, 444-456. | 2.0 | 56 |
| 84 | Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. Nature Biomedical Engineering, 2022, 6, 129-143. | 11.6 | 56 |
| 85 | Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nuclear Medicine and Biology, 2011, 38, 223-233. | 0.3 | 55 |
| 86 | An engineered protein antagonist of K-Ras/B-Raf interaction. Scientific Reports, 2017, 7, 5831. | 1.6 | 55 |
| 87 | Rapid Method for Measuring ScFv Thermal Stability by Yeast Surface Display. Biotechnology Progress, 2003, 19, 631-638. | 1.3 | 54 |
| 88 | Structural Model of the mAb 806-EGFR Complex Using Computational Docking followed by Computational and Experimental Mutagenesis. Structure, 2006, 14, 401-414. | 1.6 | 52 |
| 89 | A switchable yeast display/secretion system. Protein Engineering, Design and Selection, 2015, 28, 317-325. | 1.0 | 52 |
| 90 | Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integrative Biology (United Kingdom), 2014, 6, 388-398. | 0.6 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | A single-cell assay of Î²-galactosidase activity inSaccharomyces cerevisiae. Cytometry, 1988, 9, 394-404. | 1.8 | 50 |
| 92 | What, Why, Where, and When: Bringing Timing to Immuno-Oncology. Trends in Immunology, 2019, 40, 12-21. | 2.9 | 50 |
| 93 | Expression of the 180-kD Ribosome Receptor Induces Membrane Proliferation and Increased Secretory Activity in Yeast. Journal of Cell Biology, 1999, 146, 273-284. | 2.3 | 49 |
| 94 | CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood, 2018, 131, 611-620. | 0.6 | 49 |
| 95 | Highly<scp>l</scp>and<scp>d</scp>enantioselective variants of horseradish peroxidase discovered by an ultrahigh-throughput selection method. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17694-17699. | 3.3 | 48 |
| 96 | Engineering Fibronectin-Based Binding Proteins by Yeast Surface Display. Methods in Enzymology, 2013, 523, 303-326. | 0.4 | 47 |
| 97 | Expression Level Tuning for Optimal Heterologous Protein Secretion in Saccharomyces cerevisiae. Biotechnology Progress, 1997, 13, 117-122. | 1.3 | 46 |
| 98 | Antigen Release Kinetics in the Phagosome Are Critical to Cross-Presentation Efficiency. Journal of Immunology, 2008, 180, 1576-1583. | 0.4 | 46 |
| 99 | Emergent Properties of Nanosensor Arrays: Applications for Monitoring IgG Affinity Distributions, Weakly Affined Hypermannosylation, and Colony Selection for Biomanufacturing. ACS Nano, 2013, 7, 7472-7482. | 7.3 | 45 |
| 100 | Maximizing response to intratumoral immunotherapy in mice by tuning local retention. Nature Communications, 2022, 13, 109. | 5.8 | 45 |
| 101 | Constitutive overexpression of secreted heterologous proteins decreases extractable heavy chain binding protein and protein disulfide isomerase levels in Saccharomyces cerevisiae. Biotechnology Progress, 1995, 11, 171-177. | 1.3 | 44 |
| 102 | Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. Nature Biotechnology, 2005, 23, 191-194. | 9.4 | 44 |
| 103 | Reduction of Nonspecificity Motifs in Synthetic Antibody Libraries. Journal of Molecular Biology, 2018, 430, 119-130. | 2.0 | 44 |
| 104 | Pharmacokinetic tuning of proteinâ€“antigen fusions enhances the immunogenicity of T-cell vaccines. Nature Biomedical Engineering, 2020, 4, 636-648. | 11.6 | 44 |
| 105 | Molecular Magnetic Resonance Imaging of Tumor Response to Therapy. Scientific Reports, 2015, 5, 14759. | 1.6 | 43 |
| 106 | Interleukin 2 (IL-2) Variants Engineered for Increased IL-2 Receptor Î±-Subunit Affinity Exhibit Increased Potency Arising from a Cell Surface Ligand Reservoir Effect. Molecular Pharmacology, 2004, 66, 864-869. | 1.0 | 42 |
| 107 | Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library. Journal of Biological Chemistry, 2016, 291, 22496-22508. | 1.6 | 42 |
| 108 | Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. Journal of Experimental Medicine, 2017, 214, 1679-1690. | 4.2 | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Disulfide bond formation and eukaryotic secretory productivity. Current Opinion in Biotechnology, 1995, 6, 203-208. | 3.3 | 38 |
| 110 | Contrasting secretory processing of simultaneously expressed heterologous proteins inSaccharomyces cerevisiae. Biotechnology and Bioengineering, 2006, 93, 896-905. | 1.7 | 38 |
| 111 | Engineered Interleukin-2 Antagonists for the Inhibition of Regulatory T Cells. Journal of Immunotherapy, 2009, 32, 887-894. | 1.2 | 38 |
| 112 | Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 925-937. | 3.3 | 38 |
| 113 | Effect of Small-Moleculeâ€“Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody. Molecular Cancer Therapeutics, 2012, 11, 1365-1372. | 1.9 | 37 |
| 114 | Temporally Programmed CD8Î± + DC Activation Enhances Combination Cancer Immunotherapy. Cell Reports, 2016, 17, 2503-2511. | 2.9 | 37 |
| 115 | Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). AAPS Journal, 2016, 18, 861-875. | 2.2 | 37 |
| 116 | A graphene-based physiometer array for the analysis of single biological cells. Scientific Reports, 2014, 4, 6865. | 1.6 | 36 |
| 117 | Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer. Journal of Nuclear Medicine, 2017, 58, 1735-1742. | 2.8 | 36 |
| 118 | Dose Dependence of Intratumoral Perivascular Distribution of Monoclonal Antibodies. Journal of Pharmaceutical Sciences, 2012, 101, 860-867. | 1.6 | 35 |
| 119 | Biosynthetic polypeptide libraries. Current Opinion in Biotechnology, 1999, 10, 117-122. | 3.3 | 34 |
| 120 | Target-independent variable region mediated effects on antibody clearance can be FcRn independent. MAbs, 2016, 8, 1269-1275. | 2.6 | 34 |
| 121 | Directed evolution for improved secretion of cancerâ€“testis antigen NY-ESO-1 from yeast. Protein Expression and Purification, 2006, 48, 232-242. | 0.6 | 33 |
| 122 | The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold. Protein Engineering, Design and Selection, 2010, 23, 211-219. | 1.0 | 33 |
| 123 | A Disulfide-Free Single-Domain VL Intrabody with Blocking Activity towards Huntingtin Reveals a Novel Mode of Epitope Recognition. Journal of Molecular Biology, 2011, 414, 337-355. | 2.0 | 33 |
| 124 | Differential Requirement for CD70 and CD80/CD86 in Dendritic Cell-Mediated Activation of Tumor-Tolerized CD8 T Cells. Journal of Immunology, 2012, 189, 1708-1716. | 0.4 | 32 |
| 125 | A Flow Cytometric Assay for Screening Improved Heterologous Protein Secretion in Yeast. Biotechnology Progress, 2006, 22, 1200-1208. | 1.3 | 31 |
| 126 | Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression. Journal of Molecular Biology, 2012, 422, 532-544. | 2.0 | 30 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Engineering, Design and Selection, 2013, 26, 187-193. | 1.0 | 30 |
| 128 | Antitumor Antibodies Can Drive Therapeutic T Cell Responses. Trends in Cancer, 2017, 3, 615-620. | 3.8 | 29 |
| 129 | Phage on display. Trends in Biotechnology, 1999, 17, 423-424. | 4.9 | 28 |
| 130 | Context-dependent mutations predominate in an engineered high-affinity single chain antibody fragment. Protein Science, 2006, 15, 324-334. | 3.1 | 28 |
| 131 | Targeted Cytolysins Synergistically Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin. Molecular Cancer Therapeutics, 2013, 12, 1774-1782. | 1.9 | 27 |
| 132 | Chaperone proteins as single component reagents to assess antibody nonspecificity. MAbs, 2017, 9, 1036-1040. | 2.6 | 26 |
| 133 | Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. Protein Engineering, Design and Selection, 2012, 25, 47-57. | 1.0 | 25 |
| 134 | Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers. Cancer Research, 2016, 76, 6669-6679. | 0.4 | 25 |
| 135 | Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis. Nature Communications, 2018, 9, 1461. | 5.8 | 25 |
| 136 | Detection of amyloid Î² oligomers toward early diagnosis of Alzheimer's disease. Analytical Biochemistry, 2019, 566, 40-45. | 1.1 | 25 |
| 137 | Integrated Mimicry of B Cell Antibody Mutagenesis Using Yeast Homologous Recombination. Molecular Biotechnology, 2011, 47, 57-69. | 1.3 | 24 |
| 138 | Nonspecificity in a nonimmune human scFv repertoire. MAbs, 2017, 9, 1029-1035. | 2.6 | 24 |
| 139 | Biodistribution and Clearance of Small Molecule Hapten Chelates for Pretargeted Radioimmunotherapy. Molecular Imaging and Biology, 2011, 13, 215-221. | 1.3 | 22 |
| 140 | Tumor cells are dislodged into the pulmonary vein during lobectomy. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 3224-3231.e5. | 0.4 | 22 |
| 141 | Generation of Fluorogen-Activating Designed Ankyrin Repeat Proteins (FADAs) as Versatile Sensor Tools. Journal of Molecular Biology, 2016, 428, 1272-1289. | 2.0 | 22 |
| 142 | Propagation of an amplifiable recombinant plasmid inSaccharomyces cerevisiae: flow cytometry studies and segregated modeling. Biotechnology and Bioengineering, 1990, 35, 565-577. | 1.7 | 21 |
| 143 | Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients. MAbs, 2017, 9, 257-268. | 2.6 | 19 |
| 144 | Cutting Edge: Delay and Reversal of T Cell Tolerance by Intratumoral Injection of Antigen-Loaded Dendritic Cells in an Autochthonous Tumor Model. Journal of Immunology, 2010, 184, 5954-5958. | 0.4 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Synergistic Antitumor Activity from Two-Stage Delivery of Targeted Toxins and Endosome-Disrupting Nanoparticles. Biomacromolecules, 2013, 14, 1093-1102. | 2.6 | 18 |
| 146 | Leader peptide efficiency correlates with signal recognition particle dependence inSaccharomyces cerevisiae. , 1998, 59, 286-293. | | 17 |
| 147 | Single-chain antibody fragment-based adsorbent for the extracorporeal removal of Î²2-microglobulin. Kidney International, 2004, 65, 310-322. | 2.6 | 15 |
| 148 | Inducing Efficient Cross-priming Using Antigen-coated Yeast Particles. Journal of Immunotherapy, 2008, 31, 607-619. | 1.2 | 15 |
| 149 | Activation of Tolerogenic Dendritic Cells in the Tumor Draining Lymph Nodes by CD8+T Cells Engineered to Express CD40 Ligand. Journal of Immunology, 2010, 184, 3394-3400. | 0.4 | 15 |
| 150 | Thermodynamic characterization of affinity maturation: the D1.3 antibody and a higher-affinity mutant. , 1998, 11, 10-13. | | 14 |
| 151 | Glutathione excretion in response to heterologous protein secretion insaccharomyces cerevisiae. , 2000, 68, 389-395. | | 14 |
| 152 | Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells. International Journal of Cancer, 2013, 133, 2925-2933. | 2.3 | 14 |
| 153 | Rolling Adhesion Kinematics of Yeast Engineered To Express Selectins. Biotechnology Progress, 2003, 19, 1033-1037. | 1.3 | 13 |
| 154 | A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin. Journal of Pharmaceutical Sciences, 2015, 104, 4409-4416. | 1.6 | 13 |
| 155 | Antibody-Mediated Neutralization of Perfringolysin O for Intracellular Protein Delivery. Molecular Pharmaceutics, 2015, 12, 1992-2000. | 2.3 | 13 |
| 156 | Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs. Journal of Molecular Biology, 2017, 429, 2528-2541. | 2.0 | 13 |
| 157 | Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2019, 9, 330. | 1.3 | 12 |
| 158 | Design Principles for SuCESsFul Biosensors: Specific Fluorophore/Analyte Binding and Minimization of Fluorophore/Scaffold Interactions. Journal of Molecular Biology, 2016, 428, 4228-4241. | 2.0 | 11 |
| 159 | Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding proteins. Nucleic Acids Research, 2017, 45, 7602-7614. | 6.5 | 11 |
| 160 | Intratumorally anchored cytokine therapy. Expert Opinion on Drug Delivery, 2022, 19, 725-732. | 2.4 | 11 |
| 161 | Artificial Anti-Tumor Opsonizing Proteins with Fibronectin Scaffolds Engineered for Specificity to Each of the Murine FcÎ³R Types. Journal of Molecular Biology, 2018, 430, 1786-1798. | 2.0 | 10 |
| 162 | Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models. OncoImmunology, 2019, 8, e1558678. | 2.1 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Mathematical modeling of a single-cell enzyme assay. Biotechnology and Bioengineering, 1990, 35, 525-532. | 1.7 | 9 |
| 164 | Yeast Display and Selections. , 2010, , 207-233. | | 9 |
| 165 | A Nonpolycationic Fully Proteinaceous Multiagent System for Potent Targeted Delivery of siRNA. Molecular Therapy - Nucleic Acids, 2014, 3, e162. | 2.3 | 9 |
| 166 | A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling. Molecular Cancer Therapeutics, 2018, 17, 1773-1780. | 1.9 | 8 |
| 167 | A high affinity human antibody antagonist of P-selectin mediated rolling. Biochemical and Biophysical Research Communications, 2006, 350, 508-513. | 1.0 | 7 |
| 168 | Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA. Molecular Cancer Therapeutics, 2020, 19, 2575-2584. | 1.9 | 7 |
| 169 | The single cell as a microplate well. Nature Biotechnology, 2000, 18, 1039-1040. | 9.4 | 6 |
| 170 | Connecting the sequence dots: shedding light on the genesis of antibodies reported to be designed in silico. MAbs, 2019, 11, 803-808. | 2.6 | 6 |
| 171 | Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice. PLoS ONE, 2021, 16, e0248903. | 1.1 | 6 |
| 172 | A mathematical model of recombinational amplification of the 2Î¼ plasmid in the yeast Saccharomyces cerevisiae. Journal of Theoretical Biology, 1988, 130, 481-492. | 0.8 | 5 |
| 173 | Role of the Protein-Folding Chaperone BiP in Secretion of Foreign Proteins in Eukaryotic Cells. ACS Symposium Series, 1993, , 121-132. | 0.5 | 5 |
| 174 | Equilibrium and dynamic design principles for binding molecules engineered for reagentless biosensors. Analytical Biochemistry, 2014, 460, 9-15. | 1.1 | 5 |
| 175 | Identification of Highly Cross-Reactive Mimotopes for a Public T Cell Response in Murine Melanoma. Frontiers in Immunology, 0, 13, . | 2.2 | 5 |
| 176 | Biochemical engineering IXâ€”interdisciplinary foundations for creating new biotechnology: I. Biotechnology and Bioengineering, 1996, 52, 1-2. | 1.7 | 4 |
| 177 | Protein technologies. Current Opinion in Biotechnology, 2007, 18, 293-294. | 3.3 | 3 |
| 178 | Pre-Targeted Radioimmunotherapy Employing a Recombinant Bispecific Antibody Using a Murine Xenograft Model of Human Leukemia. Blood, 2014, 124, 3749-3749. | 0.6 | 3 |
| 179 | Coâ€Anchoring of Engineered Immunogen and Immunostimulatory Cytokines to Alum Promotes Enhancedâ€Humoral Immunity. Advanced Therapeutics, 2022, 5, . | 1.6 | 3 |
| 180 | Yeast Surface Display for Protein Engineering: Library Generation, Screening, and Affinity Maturation. Methods in Molecular Biology, 2022, 2491, 29-62. | 0.4 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Stochastic simulation of 2.mu. multicopy plasmid amplification in yeast. Biotechnology Progress, 1993, 9, 160-165. | 1.3 | 2 |
| 182 | Directed Evolution of Binding Proteins by Cell Surface Display: Analysis of the Screening Process. , 0, , 111-126. | | 1 |
| 183 | Jay Bailey as mentor?The students' perspective. Biotechnology and Bioengineering, 2002, 79, 484-489. | 1.7 | 1 |
| 184 | Exploiting bias in a non-immune human antibody library to predict antigenicity. Protein Engineering, Design and Selection, 2011, 24, 845-853. | 1.0 | 1 |
| 185 | Engineered pore-forming proteins for the intracellular delivery of macromolecular therapeutics. , 2014, , . | | 1 |
| 186 | Glutathione excretion in response to heterologous protein secretion in saccharomyces cerevisiae. , 2000, 68, 389. | | 1 |
| 187 | A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture. Blood, 2015, 126, 118-118. | 0.6 | 1 |
| 188 | Directed evolution in chemical engineering. AICHE Journal, 2005, 51, 3083-3085. | 1.8 | 0 |
| 189 | Surface Marker Analysis in the Evaluation of Pleural Effusions: Unique Markers Can Assist in Distinguishing Malignant From Nonmalignant Effusions. Chest, 2010, 138, 340A. | 0.4 | 0 |
| 190 | Biochemical engineering IX-interdisciplinary foundations for creating new biotechnology: II. Biotechnology and Bioengineering, 2010, 52, 183-183. | 1.7 | 0 |
| 191 | CD8+ T-cell Responses Rapidly Select for Antigen-Negative Tumor Cells in the Prostate. Cancer Immunology Research, 2013, 1, 393-401. | 1.6 | 0 |